In this edition, atezolizumab benefits PD-L1-selected patients with NSCLC, risks persist with e-cigarette use after quitting tobacco smoking and more. Read the full coverage here: Adjuvant atezolizumab benefits PD-L1-selected patients with NSCLC Lung cancer risks persist with e-cigarette use after quitting tobacco smoking COPD, IPF end of life health care use differs from lung cancer Tecentriq combination fails to improve survival in metastatic lung cancer Risk for lung cancer reoccurrence may be associated with OSA-related hypoxemia References: Figueroa Rodriguez F, et al. 0468: CRASH: Cancer reoccurrence is accelerated by episodic hypoxemia. Presented at: SLEEP; June 1-5, 2024; Houston. Kim Y, et al. Association of electronic cigarette use after conventional smoking cessation with lung cancer risk: A nationwide cohort study. Presented at: American Thoracic Society International Conference; May 18-22, 2024; San Diego. Press Release Suen AO, et al. Am J Respir Crit Care Med. 2024;doi:10.1154/ajrccm-conference.2024.209.1_MeetingAbstracts.A5040. Wakelee HA, et al. Abstract LBA8035. Presented at: ASCO Annual Meeting; May 31-June 4, 2024; Chicago.

Ver todos los episodios